Kaynak: MarketBeat Haber Ajansı
1 ay önce•
Hisse Senedi Orta Önem
Eli Lilly and Company Q2 Earnings Call Highlights

Eli Lilly and Company Q2 Earnings Call Highlights

Eli Lilly and Company NYSE: LLY reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising its full-year revenue and earnings guidance.
İlgili Semboller 1
LLY LLY
Kaynak: MarketBeat
Kaynağı Ziyaret Et
0 0 0
Yorum Yap
Yorumlar
0
Henüz yorum yok
Bu habere ilk yorum yapan kişi olun.